About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases and cancer.

The Company’s current product pipeline includes:

TALICIA® - An oral combination therapy for Helicobacter pylori infection, with an ongoing confirmatory Phase III study and successful results from a first Phase III study.

RHB-104 - An oral combination therapy with an ongoing first Phase III study for Crohn's disease and a planned pivotal Phase III study for nontuberculous mycobacteria (NTM) infections.

BEKINDA® (RHB-102) - A once-daily oral pill formulation of ondansetron with positive results from a Phase III study for acute gastroenteritis and gastritis and positive results from a Phase II study in IBS-D.

YELIVA® (ABC294640) - an orally-administered, first-in-class SK2 selective inhibitor with an ongoing Phase IIa study for cholangiocarcinoma.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

RHB-107 (MESUPRON) - A Phase II-stage, orally-administered, first-in-class protease inhibitor, targeting pancreatic cancer and inflammatory gastrointestinal diseases. 

RedHill promotes three gastrointestinal products in the U.S.:

Donnatal® - a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis.

Esomeprazole Strontium Delayed-Release Capsules 49.3 mg - a prescription proton pump inhibitor indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal conditions.

EnteraGam® - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.